The PHENOSAR trial: Antibiotic treatment of biopsy confirmed phenotypes in sarcoidosis: a proof of concept clinical trial.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513534-38-00

Acronym

NL73729.100.21

Enrollment

Registered

2024-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcoidosis

Brief summary

Reduction of sarcoidosis related inflammation.

Interventions

DRUGDOXICLAT 100 mg comprimidos recubiertos con película

DRUGAzithran 500 mg επικαλυμμένα με λεπτό υμένιο δισκία

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Reduction of sarcoidosis related inflammation.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026